TOCA Research and Charts

TOCA - Tocagen Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-06-30)

Last 12.93	Change ⇑ +0.68 (+5.55%)	Volume 98,875
	Open 12.25	High 13.28	Low 11.50

8EMA (Daily) 12.41	40EMA (Daily) 10.52	50EMA (Daily) 10.20	STO (Daily) 24.244	MACD Hist (Daily) -0.300
8EMA (Weekly) 11.360	40EMA (Weekly) 9.60	50EMA (Weekly) 9.07	STO (Weekly) 69.885	MACD Hist (Weekly) 1.243


Company Profile
Tocagen Inc is a clinical-stage, cancer-selective gene therapy company. It is focused on developing product candidates designed to activate a patient's immune system against their own cancer from within. The company's cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Tocagen is developing product candidate, Toca 511 and Toca FC, for the treatment of recurrent high grade glioma, or HGG, a brain cancer with limited treatment options, low survival rates and, therefore, a significant unmet medical need. The company has obtained Fast Track Designation from the U.S. Food and Drug Administration for Toca 511 and Toca FC.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.